Merck Patient Assistance Program - NeedyMeds
Vytorin. Merck Patient Assistance Program. This program provides brand name medications at no or low cost. Provided by Merck Patient Assistance, Inc. This is a securities action that has been certified by the Court to proceed as a class action on behalf of all persons and entities that purchased or acquired Merck. Dec 16, 2015. As the title indicates, this was a large trial designed to determine whether Vytorin, Merck's heart drug that combines ezetimibe with simvastatin.
Merck & Co. Inc. Vytorin-Related Bernstein Litowitz Berger.
Merck Connect has partnered with Physicians Interactive® to bring eligible practitioners a process to request available samples, coupons, and/or vouchers for. Apr 26, 2017. versions of Merck's Vytorin ezetimibe/simvastatin for the treatment of. No incremental benefit of Vytorin on cardiovascular morbidity and. Packager Merck Sharp & Dohme Corp. Category. These highlights do not include all the information needed to use VYTORIN safely and effectively. See full.
Merck's Vytorin Study Epitomizes Inherent Risks Of Major Clinical.
Mar 8, 2013. Sometime this month, a group of independent experts will look at the data for the key study testing Merck's blockbuster cholesterol pills, Zetia. May 2, 2017. Patent expirations, particularly for the heart drugs Zetia and Vytorin, cost Merck nearly $700 million in sales in the quarter, and the company.
Ezetimibe/simvastatin - Wikipedia
Ezetimibe/simvastatin is a drug combination used for the treatment of dyslipidemia. It is a. were approved in 2017. The combination preparation is marketed by Merck & Co. under the trade names Vytorin in the US and Inegy in Europe. Welcome to the information website for In re Merck & Co. Inc. Vytorin/Zetia Securities Litigation the "Action". Please be advised that Lead Plaintiffs, Stichting.